Partridge S E, Lowdell C P
Department of Clinical Oncology, St Thomas' Hospital, London, UK.
Clin Oncol (R Coll Radiol). 1999;11(3):187-9. doi: 10.1053/clon.1999.9039.
Cases of myelodysplastic syndrome occurring after multi-drug chemotherapy are rare; they are more often associated with the use of alkylating agents. We report the case history of a patient with myelodyspasia occurring after neoadjuvant methotrexate, mitoxantrone and mitomycin C (triple M) chemotherapy with subsequent radiotherapy for locally advanced breast cancer. Cytogenetic analysis of a bone marrow biopsy confirmed the typical chromosomal abnormalities associated with therapy related myelodysplasia. Few treatments for this disorder have been found to be of value. The aetiology, incidence and management options are briefly discussed.
多药化疗后发生骨髓增生异常综合征的病例很少见；它们更常与烷化剂的使用有关。我们报告了一名患者的病史，该患者在新辅助甲氨蝶呤、米托蒽醌和丝裂霉素C（三联M）化疗后发生骨髓发育不良，随后接受局部晚期乳腺癌放疗。骨髓活检的细胞遗传学分析证实了与治疗相关的骨髓发育异常相关的典型染色体异常。已发现很少有治疗这种疾病的方法有价值。本文简要讨论了其病因、发病率和治疗选择。
